Eupraxia Pharmaceuticals Reaches EoE Trial Enrollment; Q3 Loss $15.2M
Eupraxia Pharmaceuticals Inc. announced its third quarter 2026 financial results, highlighting significant progress in its RESOLVE trial for Eosinophilic Esophagitis (EoE). The company reached target enrollment for the Phase 2b portion and anticipates interim analysis in December 2026. Positive data from the Phase 1b/2a trial showed durable treatment effects, with 64% of patients remaining in clinical remission over 52 weeks. Eupraxia also reported a net loss of $15.2 million for the quarter but confirmed a cash runway extending into the second half of 2028.
Key Highlights
- Reached target enrollment of 120 patients in Phase 2b RESOLVE trial for Eosinophilic Esophagitis (EoE).
- Phase 2b interim analysis of RESOLVE trial expected in December 2026.
- Cash runway extends into the second half of 2028.
- Reported net loss of $15.2 million for Q3 2026, compared to $6.4 million in Q3 2025.
- Cash and cash equivalents plus short-term investments totaled $126.4 million as of September 30, 2026.
- Observed 64% of patients in clinical remission over 52 weeks in Phase 1b/2a trial data.
- Odynophagia scores reduced from 62% at baseline to 25% post-treatment in Phase 1b/2a trial.
Price Impact
More from EPRX
Eupraxia Pharmaceuticals to Sell Up to $300M in Common Shares via Agents Agreement
Eupraxia Pharmaceuticals Establishes $125M At-The-Market Offering Program
Eupraxia Pharmaceuticals to Present EoE Trial Data at ACG and UEG Conferences